Cargando…

PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study

Immunotherapy with check-point inhibitors serves as a promising treatment strategy in patients with upper gastrointestinal (GI) tumors. Human epidermal growth factor receptor 2 (HER2) is the only identified therapeutic target in upper GI tumors, whose potential interaction with programmed death-liga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beer, Andrea, Taghizadeh, Hossein, Schiefer, Ana-Iris, Puhr, Hannah C., Karner, Alexander K., Jomrich, Gerd, Schoppmann, Sebastian F., Kain, Renate, Preusser, Matthias, Ilhan-Mutlu, Aysegül
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471145/ https://www.ncbi.nlm.nih.gov/pubmed/32372174 http://dx.doi.org/10.1007/s12253-020-00814-2

Ejemplares similares

Clinical characteristics and comparison of the outcome in young versus older patients with upper gastrointestinal carcinoma
por: Puhr, Hannah Christina, et al.
Publicado: (2020)

Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
por: Puhr, Hannah Christina, et al.
Publicado: (2020)

Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma
por: Puhr, Hannah C., et al.
Publicado: (2023)

Elevated Free Thyroxine Levels Are Associated with Poorer Overall Survival in Patients with Gastroesophageal Cancer: A Retrospective Single Center Analysis
por: Puhr, H. C., et al.
Publicado: (2019)

New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?
por: Puhr, Hannah Christina, et al.
Publicado: (2020)

Recent Advances in the Systemic Treatment of Localized Gastroesophageal Cancer
por: Puhr, Hannah Christina, et al.
Publicado: (2023)

Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity
por: Paireder, Matthias, et al.
Publicado: (2020)

Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy
por: Jomrich, Gerd, et al.
Publicado: (2021)

Immunotherapy for Esophageal Cancers: What Is Practice Changing in 2021?
por: Puhr, Hannah Christina, et al.
Publicado: (2021)

MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2018)

Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction
por: Feka, Joy, et al.
Publicado: (2023)

Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis
por: Puhr, Hannah C., et al.
Publicado: (2021)

The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction
por: Jomrich, Gerd, et al.
Publicado: (2018)

Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score)
por: Puhr, H.C., et al.
Publicado: (2022)

New emerging targets in cancer immunotherapy: the role of LAG3
por: Puhr, Hannah Christina, et al.
Publicado: (2019)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy
por: Puhr, Hannah C., et al.
Publicado: (2022)

High Mean Corpuscular Volume Predicts Poor Outcome for Patients With Gastroesophageal Adenocarcinoma
por: Jomrich, Gerd, et al.
Publicado: (2019)

Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors
por: Kristo, Ivan, et al.
Publicado: (2018)

Silent Gastroesophageal Reflux Disease in Patients with Morbid Obesity Prior to Primary Metabolic Surgery
por: Kristo, Ivan, et al.
Publicado: (2020)

External validation of the NUn score for predicting anastomotic leakage after oesophageal resection
por: Paireder, Matthias, et al.
Publicado: (2017)

Targeted therapy in gastric cancer
por: Jomrich, G., et al.
Publicado: (2016)

NephroCheck data compared to serum creatinine in various clinical settings
por: Pajenda, Sahra, et al.
Publicado: (2015)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

The role of magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease
por: Bonavina, Luigi, et al.
Publicado: (2021)

How we treat esophageal squamous cell carcinoma
por: Puhr, H.C., et al.
Publicado: (2023)

Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours
por: Mair, Maximilian J, et al.
Publicado: (2020)

Electrical lower esophageal sphincter augmentation in patients with GERD and severe ineffective esophageal motility—a safety and efficacy study
por: Paireder, Matthias, et al.
Publicado: (2019)

Effect of electrical stimulation therapy of the lower esophageal sphincter in GERD patients with ineffective esophageal motility
por: Paireder, Matthias, et al.
Publicado: (2020)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
por: Zhao, Dan, et al.
Publicado: (2019)

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma
por: Mair, Maximilian J., et al.
Publicado: (2021)

Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma
por: Sigrand, Julie, et al.
Publicado: (2016)

Gene Signal Distribution and HER2 Amplification in Gastroesophageal Cancer
por: Jørgensen, Jan Trøst, et al.
Publicado: (2017)

Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2016)

Results of Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease
por: Schwameis, Katrin, et al.
Publicado: (2018)

Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer
por: Jomrich, G., et al.
Publicado: (2017)

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
por: Catenacci, D.V.T., et al.
Publicado: (2022)

Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
por: Kollmann, Dagmar, et al.
Publicado: (2017)

Schizophrenia and gastroesophageal reflux symptoms
por: Kasap, Elmas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_bme862oatth6d0bcofprhihqtt